TY  - GEN
AU  - Yaktapour,Niuscha
AU  - Meiss,Frank
AU  - Mastroianni,Justin
AU  - Zenz,Thorsten
AU  - Andrlova,Hana
AU  - Mathew,Nimitha R
AU  - Claus,Rainer
AU  - Hutter,Barbara
AU  - Fröhling,Stefan
AU  - Brors,Benedikt
AU  - Pfeifer,Dietmar
AU  - Pantic,Milena
AU  - Bartsch,Ingrid
AU  - Spehl,Timo S
AU  - Meyer,Philipp T
AU  - Duyster,Justus
AU  - Zirlik,Katja
AU  - Brummer,Tilman
AU  - Zeiser,Robert
TI  - BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia
SN  - 1558-8238
PY  - 2015///0302
KW  - Antineoplastic Agents
KW  - adverse effects
KW  - Cell Line, Tumor
KW  - Cell Proliferation
KW  - Cell Survival
KW  - drug effects
KW  - Extracellular Signal-Regulated MAP Kinases
KW  - metabolism
KW  - Humans
KW  - Indoles
KW  - Intracellular Signaling Peptides and Proteins
KW  - antagonists & inhibitors
KW  - Leukemia, Lymphocytic, Chronic, B-Cell
KW  - chemically induced
KW  - MAP Kinase Signaling System
KW  - Melanoma
KW  - drug therapy
KW  - Middle Aged
KW  - Mutation, Missense
KW  - Phosphorylation
KW  - Protein Processing, Post-Translational
KW  - Protein-Tyrosine Kinases
KW  - Proto-Oncogene Proteins B-raf
KW  - Radionuclide Imaging
KW  - Skin Neoplasms
KW  - Sulfonamides
KW  - Syk Kinase
KW  - Treatment Outcome
KW  - Vemurafenib
N1  - Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1172/JCI76539
ER  -